LCC has announced that Dr Steven Powell has been appointed to the Board of the Company as a Non-Executive Chair.
Steven is a dedicated life-science professional with a proven track record; he has supported several companies’ developments and exits over an extensive period. His experience is ideally placed to guide LCC’s continued strategic development, and we are thrilled to have him on board our journey.
In line with our transition from a CRO to a biotechnology company, Liverpool ChiroChem Ltd has officially been renamed to ‘LCC Therapeutics Ltd’. LCC Therapeutics is developing best-in-class small molecule therapeutics. We have built and validated our platform over 10...
Liverpool ChiroChem Ltd. (hereinafter referred to as “LCC”) and Veritas In Silico Inc. (hereinafter referred to as “VIS”) announce that LCC and VIS have entered into a Collaboration Development & Commercialisation Agreement today to jointly generate mRNA-targeted...
LCC is transitioning from a CRO to a hub-and-spoke biotech company, generating small molecule lead candidate assets against oncology and rare disease targets. LCC built and validated its chemistry platform over 10 years via successful delivery across multiple target...